US: Rare disease research hopeful, but therapy success remains low
This article was originally published in SRA
Executive Summary
It used to be that the regulatory focus of the US Food and Drug Administration on therapies to treat rare diseases involved only a small segment of the agency's activities. Now, however, "it is pervasive", according to Gayatri Rao, director of the FDA's Office of Orphan Product Development.